Oxford, UK 12 July 2011 – PharmaVentures Limited, experts in deals and alliances, are pleased to announce that they have been engaged by Avexa Limited to seek an out-licensing partner for apricitabine (ATC), a late-stage, novel treatment for HIV infection. The engagement will utilise PharmaVentures’ global transactional expertise in the healthcare and investment business sectors.

Dr Fintan Walton, CEO, PharmaVentures commented, “We are delighted to have been chosen by Avexa to assist in achieving its business goal of maximising the return on investment in its development compound apricitabine (ATC). With 20 years’ experience of deals and alliances, PharmaVentures can provide Avexa with immediate access to extensive licensing expertise and a network of key decision makers in relevant companies”

Iain Kirkwood, Chairman of Avexa said, “the appointment of PharmaVentures to work with and complement our management team is the next logical step in the commercialisation of ATC following our successful regulatory meeting with the FDA earlier this year. PharmaVentures have an excellent reputation and track record in this area.”

ATC is a novel nucleoside, a class of compound known to be a vital component of anti-HIV therapy. ATC offers a new extension to existing therapies in the treatment of drug-resistant HIV, especially for those patients with limited remaining therapeutic options.

PharmaVentures is a leading life sciences transaction advisory firm with strong capabilities in finding and evaluating opportunities and negotiating deals. The licensing team has an established track record in generating outstanding value for PharmaVentures’ clients and has assisted in over 100 transactions in the past 20 years.

For enquiries regarding this licensing opportunity or how we can help your company to achieve its business goals, please contact:

Kevin Bottomley

Head of Transactions

PharmaVentures Ltd.

+44 7931 144097

– ends –

Oxford UK, 28 June 2011: PharmaVentures, experts in deals and alliances, are pleased to announce that they have recently been engaged by two major pharmaceutical companies to divest three facilities in three continents:

These new M&A mandates follow fast on the imminent closure of a sale of a European R&D facility and the successful divestment of three facilities for UCB and two for sanofi.

Fintan Walton, CEO of PharmaVentures, commented ” At PharmaVentures we are seeing an increasing number of top tier pharmaceutical companies looking to divest facilities as a result of consolidation or restructuring within their businesses. They trust PharmaVentures to provide the specialist skills and experience in valuing and positioning their assets for sale and then conducting a thorough proven process to deliver the best outcome. We are delighted that so many of the top Pharmaceutical companies recognise us as the provider of choice for these services.”

Kevin Bottomley, Head of Transactions stated ” Many of these facilities are very specialist and require expert knowledge to understand and convey the true value to potential acquirers. In selling these sites for continued or new uses we have been able to secure the future employment of thousands of people and facilitate new business growth.”

PharmaVentures is a leading life sciences transaction advisory firm with strong capabilities in finding and evaluating opportunities and negotiating deals. The transaction team has an established track record in generating outstanding value for PharmaVentures’ clients and has assisted in over 100 transactions in the past 20 years. Beyond that, PharmaVentures’ senior advisors have assisted over 500 leading companies in their growth needs including the areas of partnering and M&A.

– ends –

Oxford, UK- June 27 2011: PharmaDeals®, the publishing division of PharmaVentures, announced today the launch of PharmaDeals v4 Enterprise Edition, a new integrated resource with a comprehensive, searchable and interactive library of reports, articles, agreements, video, graphs and deal data. As well as access to new online content, the resource also provides users with a range of applications and tools for tracking, alerting and analysing information.

Fintan Walton, Chief Executive of PharmaVentures, the experts in deals and alliances, says, “Our research shows that pharma and biotech deal makers have to be increasingly more creative to secure the deals that count. Understanding the nature and extent of this new generation of deals is critical, as is a firm grasp of the established benchmarks and methodologies for deal making.” Dr Walton continues, “Against this background, it’s perhaps not surprising that our customers have expressed a need for a single point of access to our extensive range of deal making resources – whether it’s a ‘how to’ guide, our expert analysis of trends, or direct access to the most comprehensive bank of industry data and agreements. But they want speed and ease of access too, irrespective of the type or source of information.”

Anne Vindenes Allen, PharmaDeals’ Executive Director, adds, “Our range of customers need to access and use our data and expertise in different ways, and this is addressed withPharmaDeals v4 Enterprise Edition. Market research, marketing and brand managers use the product to track competitors’ deal making activities and stay apprised of the deal making arena. Business intelligence, business development, strategic planning and licensing executives use this vital information to empower their business decisions and benchmark deals. Furthermore, information about industry deals is valuable to R&D, discovery, financial institutions, and consultants. Through creating a fully online resource, and making it easier for our customers to see the full context through intelligent linking and classification, we have just made it possible for them to find all the key deal making information they need in one place”. PharmaDeals are currently taking applications for company-wide demonstrations and trials to the new resource.

– ends –

PharmaVentures today announced the appointment of Ping Shek as Senior Director in the Transactions division of Corporate Advisory working on a number of key M&A and divestment mandates in the healthcare business sector.

Fintan Walton, PhD, PharmaVentures’ Chief Executive Office says “We are delighted to welcome Ping to PharmaVentures. Our Transactions division is currently working with a number of key companies in the life sciences sector, providing a comprehensive M&A and asset divestment service and has recently celebrated successes for a number of clients including UCB, Sanofi, Helsinn and Dow Chemical. Our client portfolio will benefit from this key appointment to the team.”

Kevin Bottomley, Head of Transactions says “Ping brings substantial healthcare and investment banking experience into PharmaVentures and has a track record of mandate origination and transaction execution from his previous posts. His broad experience and knowledge will be invaluable to our clients looking to optimise business assets, engaging acquirers and ensuring rapid closure of deals at the best value.”

Ping is a physics graduate from Oxford and has an MBA (with a distinction in Advanced Corporate Finance) from the London Business School. He has previously worked with investment bankers Morgan Stanley International, Lazard Brothers, JP Morgan, Monitor Group and the Anglo Chinese Group.

For further information

Fintan Walton, CEO

+44 1865 332733

odette.hodder@pharmaventures.com

– ends –

Oxford, UK, 22nd February 2011: PharmaDeals® research has revealed that the early stages of recovery are now evident within pharmaceutical deal making activity. The overall number of deals in 2010 grew relative to 2009, and whilst collaborative R&D deals continue to decline in numbers and value, licensing activity is on the increase.

Fintan Walton, PhD, Chief Executive of PharmaVentures says, “The current deal making landscape in the life science industry is fascinating, and reflects the forces for change operating worldwide. For example, research based on our PharmaDeals database shows that deal structures for M&A transactions are becoming more and more complex, yet values are declining. In order to benefit, small and large companies alike will require increasing levels of sophistication in terms of their deal-making ability.” The results were recently presented by Dr Walton at the Sachs 4th Annual European Life Sciences CEO Forum for Partnering & Investing held in Zurich, and through analysis published by the journal PharmaDeals Review.

Anne Vindenes Allen, Executive Director for PharmaDeals, explains, “It is vital for industry deal makers to keep pace with these developments and use best available business intelligence. Analysis of our PharmaDeals data shows the variation in values within different deals types, as well as within development stages and therapy areas. We always go the extra mile to source and classify critical information to help our clients distil critical intelligence.”

Fintan Walton concludes, “Our consultants help bring companies together to further their mutual aims – it’s all about teasing out the win-win scenarios. Without an appreciation for what others are doing in the industry, that is pretty much an impossible task”.

Journal available at pharmadealsreview.com

Information about PharmaDeals v4 Agreements is available atpharmadeals.net/agreements or contact us today.

For further information:

Anne Vindenes Allen

Executive Director, PharmaDeals

+44 (0) 1865 332700

anne.allen@pharmaventures.com

– ends –

Oxford, UK, August 19 2010: PharmaVentures, the company behind the PharmaDeals® range of business information, announced today the expansion of its PharmaDeals Agreements coverage that includes exclusive interviews with deal makers around the world. The announcement follows major enhancement of its dedicated, market leading platform delivering deal data and information to the pharmaceutical and biotechnology sector.

The scope of PharmaDeals Agreements database has been expanded to include categories of deals that have medical and therapeutic applications in cosmetics, internet and e-commerce, nutritional supplements, packaging, wound care, bioterrorism, as well as deeper classifications within drug delivery technologies.

Fintan Walton, PhD, Chief Executive of PharmaVentures says, “We are very excited about our latest version of PharmaDeals. One of the big issues that face those in researching and analysing deals is the lack of scope within databases they use which is a result of the huge changes taking place in the world of deal making. More companies are doing specialist deals, for example, with orphan drugs, and the world is changing as new technologies, mechanisms of action and even new therapy areas emerge. Frankly no one else has tried to come up with solutions to these changes.”

New content is also being sourced related to deal making by Clinical Research and Contract Manufacturing Organizations. The development to the database augments recent improvements to the classifications and user interface.

As deal making is a people business subscribers can for the first time access exclusive television interviews with the key deal makers in the major pharmaceutical companies as well as key influencers at the corporate level such as CEOs and Board Members of corporations.

Dr Walton continues, “A key priority for us is to better serve our customers with information about deals from rapidly developing markets, and we have done this by considerably increasing our sources, especially in India, China, and generally within South Asia and South America. These developments to our content are additional key milestones for us, and, in the very near future, we shall be bringing news of further offerings to help our clients’ ability to win the best deals for them.”

– ends –